A5077290507- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Growth Hormone and Insulin-like Growth Factors
- Pancreatic and Hepatic Oncology Research
- SARS-CoV-2 and COVID-19 Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- COVID-19 Clinical Research Studies
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Cancer, Stress, Anesthesia, and Immune Response
- Radiomics and Machine Learning in Medical Imaging
- Long-Term Effects of COVID-19
- Renal cell carcinoma treatment
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Gut microbiota and health
- Hormonal Regulation and Hypertension
- Lung Cancer Research Studies
- MRI in cancer diagnosis
- Frailty in Older Adults
- Cancer Research and Treatments
- Blood disorders and treatments
The University of Texas MD Anderson Cancer Center
2020-2024
Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed evaluate the safety and tolerability of perioperative immunotherapy resectable carcinoma.
Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), on an upward trajectory. Immune checkpoint inhibitors (ICIs) that block T cell inhibitory receptor PD-1 were approved for treatment all HCC types. However, only a minority patients show robust and sustained response to blockade, calling improved understanding factors negatively impact rate duration discovery new adjuvant treatments...
Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including continuation ICI, treatment switching tyrosine kinase (TKIs) and cessation anticancer therapy. We sought characterise relationship between radiological patterns survival post-ICI, also appraising strategies.
4599 Background: In resectable hepatocellular carcinoma (HCC) surgical resection is associated with high recurrence rates. However, there no approved neoadjuvant or adjuvant therapies yet. Neoadjuvant immunotherapy effect has never been reported in this setting HCC. Methods: This a randomized phase II trial of nivolumab (Arm A) + ipilimumab B) as peri-operative treatment for patients (pts) HCC who are eligible resection. Pts Arm A given 240 mg iv, every 2 weeks (wks) total 3 doses followed...
BACKGROUND A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation ICI. Deaths are reported in < 5% patients treated with There are, however, no reliable markers predict the onset and severity IrAEs. We tested association between neutrophil-lymphocyte ratio (NLR) platelet-lymphocyte (PLR) at baseline development clinically...
BACKGROUND: Circulating tumor DNA (ctDNA) is a promising non-invasive marker for detection, diagnosis, treatment selection, and prognosis of hepatocellular carcinoma (HCC). OBJECTIVE: This study aimed to examine the utility ctDNA as prognostic predictive tool in HCC patients treated with nivolumab. METHODS: We analyzed pre-treatment from 44 using comprehensive genomic testing on commercially available platform. utilized log rank test univariate Cox models correlate overall survival (OS)...
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at advanced stage, which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. Therefore, the majority of HCC require systemic therapy. Nonetheless, currently approved therapies have limited effects, particularly in and resistant disease. Hence, there a critical need to identify new molecular targets effective improve outcome. The...
Atezolizumab/bevacizumab (A/B) is now a standard first-line treatment for advanced hepatocellular carcinoma (HCC), but the optimal second-line regimen not known. We evaluated real-world patterns and outcomes to investigate factors associated with post-progression survival (PPS). In this multicenter, international, retrospective study, we examined clinical characteristics of patients HCC who progressed on A/B. The primary outcome PPS was defined as time from first radiographic progression A/B...
// Yehia I. Mohamed 1 , Dan G. Duda 2 Muhammad O. Awiwi 3 Sunyoung S. Lee Lina Altameemi 4 Lianchun Xiao 5 Jeffrey Morris 6 Robert A. Wolff Khaled M. Elsayes Rikita Hatia 7 Aliya Qayyum Shadi Chamseddine Asif Rashid 8 James C. Yao Armeen Mahvash 9 Manal Hassan Hesham Amin 10 and Ahmed Omar Kaseb Department of Gastrointestinal Medical Oncology, The University Texas MD Anderson Cancer Center, Houston, TX 77030, USA Steele Laboratories, Radiation Massachusetts General Hospital Harvard School,...
There is an urgent need for oral drug the treatment of mild to moderate outpatient SARS-CoV-2. Our preclinical and clinical study’s aim was determine safety preliminary efficacy TQ Formula (TQF), in In a double-blind, placebo-controlled phase 2 trial, we randomly assigned (1:1 ratio) non-hospitalized, adult (>18 years), symptomatic SARS-CoV-2 patients receive TQF or placebo. The primary endpoints were median time-to-sustained-clinical-response (SCR). SCR 6 days arm vs. 8 placebo (p = 0.77),...
Background In patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease development hepatocellular carcinoma (HCC). We aimed investigate whether beta blockers (BBs), which mediate hypertension, conferred survival benefits in treated immune checkpoint inhibitors (ICIs). Methods conducted a retrospective, observational study 578 unresectable HCC ICI...
Background and Aims Therapeutic, clinical trial entry stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using staging systems small numbers of empirically selected variables that insufficiently account differences in biological characteristics individual patients’ disease. Approach Results We propose an approach constructing risk scores from circulating biomarkers produce a global characterization patient’s Plasma samples were collected...
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Sativa. TQF consists TQ with favorable concentration and fatty acids, including palmitic, oleic, linoleic acids. In this study, we aimed investigate the roles individual ingredients on infection SARS-CoV-2 variants
Immune checkpoint inhibitors (ICIs), agents that stimulate T-cell function, have become the standard first-line treatment for unresectable hepatocellular carcinoma (HCC). However, they may also cause immune-related adverse events (irAEs), which are rare and not been extensively reported. Here, we describe a case of severe febrile neutropenia pancytopenia after atezolizumab plus bevacizumab (atezo/bev) therapy its course.
Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 a role development hepatocellular carcinoma (HCC); however, its prognostic value has not been validated. The aim our study was to evaluate clinical patients with HCC.
The microbiome is pivotal in maintaining health and influencing disease by modulating essential inflammatory immune responses. Hepatocellular carcinoma (HCC), ranking as the third most common cause of cancer-related fatalities globally, influenced gut through bidirectional interactions between liver, evidenced both mouse models human studies. Consequently, biomarkers based on microbiota represent promising non-invasive tools for early detection HCC. There a growing body evidence suggesting...
The most common cause of death in advanced/metastatic hepatocellular carcinoma (HCC) is liver failure due to tumor progression. While retrospective studies and meta-analyses systemic therapy combined with liver-directed have been performed, prospective safety/efficacy antiangiogenesis followed by intra-arterial therapies are lacking. We tested our hypothesis that sorafenib yttrium 90 glass microspheres (90Y GMs) safe survival outcomes may improve controlling hepatic tumors.We enrolled 38...
To identify prognostic clinical and radiologic features in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab.Clinical imaging records of HCC were retrospectively reviewed, baseline recorded. Patients' studies used to determine the patients' overall survival (OS) progression-free (PFS). Univariate multivariate analyses performed features. Subanalyses treatment-naïve (who never received local or systemic therapy) previously also...
Background: The Child–Turcotte–Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). CTP stratification accuracy has been questioned attempts have made improve objectivity of system. Serum insulin-like growth factor-1 (IGF-1)-CTP proposed prognostic accuracy. We aimed validate IGF-CTP our patient population. Patients Methods: A total 84 diagnosed HCC patients were enrolled prospectively. scores addition calculated....
Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis hepatocellular carcinoma (HCC). However, the predictive prognostic value of circulating ILs is yet to be validated. Our study aimed evaluate association serum with overall survival (OS) clinicopathologic features a large cohort HCC patients. Methods: We prospectively collected samples from...
Introduction: Perioperative immunotherapy has shown promise in some patients with early-stage hepatocellular carcinoma (HCC). This study examined tissue and imaging biomarkers associated pathologic response a phase II clinical trial resectable HCC. Methods: Analysis included 18 biopsy-proven HCC treated neoadjuvant nivolumab plus ipilimumab or alone at MD Anderson Cancer Center (NCT03222076). Liver MRE (to measure fibrosis) biopsies evaluate immune activation markers) were obtained serially...